Jenscare Unveils Groundbreaking Heart Valve Technologies
Recently, Jenscare Scientific Co., Ltd. (HKEX: 9877), an innovative player in the medical device industry, showcased its extensive multi-product portfolio at TCT 2025. This included promising clinical outcomes from the TRINITY trial of LuX-Valve Plus, as well as updates on the JensClip and Ken-Valve systems. These advancements highlight the company's commitment to pioneering solutions in structural heart disease management.
Insights from the TRINITY Trial of LuX-Valve Plus
During this event, Professor Thomas Modine revealed notable 6-month follow-up results from the TRINITY trial. Aimed at assessing the safety and effectiveness of the LuX-Valve Plus in patients with severe tricuspid regurgitation, this global trial enrolled 161 patients across 20 centers. Such comprehensive engagement emphasizes the importance of shared knowledge in addressing high surgical risk and complex heart conditions.
Patient Demographics and Clinical Results
The participants had an average age of 77, with various comorbidities making surgical intervention even more challenging. The device success rate was impressive at approximately 97%, while the average procedure duration stood at around 41.60 minutes. Safety metrics revealed a 6-month composite event rate of 19.9%, with low instances of heart complications, signaling a robust performance of the device.
Long-Term Efficacy and Safety
Significant improvements were seen in tricuspid regurgitation grades and overall patient quality of life after six months. With 94.4% of patients showing no more than moderate TR and a remarkable increase in their Kansas City Cardiomyopathy Questionnaire scores, the results underscore LuX-Valve Plus's potential in improving patient outcomes. The follow-up for TRINITY is expected to provide further insights into the long-term benefits of this innovative technology.
One-Year Results from the JensClip System
Shifting focus to another key device, the JensClip TMVr system, Professor Vinicius Esteves shared compelling one-year follow-up findings from its multicenter trial. This study involved 114 patients facing symptomatic degenerative mitral regurgitation. With an outstanding device success rate of 95%, it's evident that JensClip is paving the way for safer surgical alternatives.
Safety and Efficacy Highlights
The findings demonstrated all-cause mortality at just 1.8%, and 96.29% of patients observed no trace of significant mitral regurgitation after one year. These effective results highlight JensClip’s reliability, giving clinicians confidence in treating patients with severe mitral valve issues.
Results of Ken-Valve in Aortic Valve Conditions
Professor Anson Cheung then presented the one-year outcomes of the Ken-Valve TAVR system, focusing on patients with symptomatic aortic regurgitation or a combination of aortic stenosis. The trial included 142 patients and reported an impressive device success rate of 97%, along with highly favorable patient quality of life outcomes.
Improving Treatment Options
Significantly, the majority of patients exhibited reduced aortic regurgitation after one year, with 94.7% achieving satisfactory results. Ken-Valve’s innovative design allows it to accommodate complex anatomical challenges, providing critical options for patients where previous treatments were less effective.
Overview of Jenscare’s Commitment and Future
Jenscare continues to solidify its position as a leader in the medical device sector. The groundbreaking technologies—LuX-Valve Plus, JensClip, and Ken-Valve—showcase their relentless pursuit of innovation in heart valve therapies. As Jenscare expands its operations globally, its influence in the treatment of structural heart diseases is set to grow, ensuring more patients can benefit from advanced medical solutions.
About Jenscare Scientific
Established in 2011, Jenscare is at the forefront of developing advanced interventional treatment options for various structural heart diseases. With a focus on clinical application and efficiency, the company aims to enhance patient outcomes significantly through its cutting-edge technologies.
Frequently Asked Questions
What is the purpose of the TRINITY trial for LuX-Valve Plus?
The TRINITY trial aims to evaluate the safety and effectiveness of the LuX-Valve Plus in patients with severe tricuspid regurgitation and high surgical risk.
What were the key findings from the JensClip trial?
The JensClip trial reported a 95% device success rate and significant improvements in patient outcomes, with most patients showing no significant mitral regurgitation after one year.
How has Ken-Valve performed in treating aortic valve conditions?
Ken-Valve demonstrated a 97% device success rate, with vast improvements in quality of life and significant reductions in aortic regurgitation in patients treated.
What distinguishes LuX-Valve Plus from other devices?
LuX-Valve Plus features innovative design elements that ensure high safety and operational efficiency while accommodating a wide range of valve anatomies.
What future developments can we expect from Jenscare?
Jenscare plans to continue expanding its global footprint and is committed to advancing its product offerings in the structural heart domain for better patient care.
